KRAS and Miyoshi myopathy: An unsupervised clustering of the cell lines by their DSS profiles showed that MM cell lines with PI3K and NRAS/KRAS mutations displayed high sensitivity to MEK and PI3K inhibitors, respectively (Figure 1A).